Resistencia antimicrobiana

COMBACTE-CARE

Combatting Bacterial Resistance in Europe - Carbapenem Resistance

Duración
01/03/2015 - 28/02/2020
Coordinador
Jordi Vila
Financiadores
Innovative Medicines Iniciatives 2 (IMI-2)

Infections caused by bacteria known as ‘carbapenem-resistant enterobacteriaceae’ (CRE) are resistant to most available antibiotics and are so difficult to treat they are considered to be one of the most dangerous drug-resistant bacteria in the world. Worryingly, cases of CRE infections are on the rise in Europe and globally.

The COMBACTE-CARE project aims to shed new light on the best ways to understand and treat CRE infections. It will also run clinical trials of a novel antibiotic combination product designed to tackle a sub-type of CRE infections for which there are limited or no treatment options.

Otros proyectos

Ver proyectos pasados

COMBACTE

Combatiendo la Resistencia Bacteriana en Europa

Xpatial-TB

Improved case detection through TB contact risk stratification by Xpert results and spatial parameters in Mozambique

WHIP3TB

Evaluation of the effect of weekly high dose rifapentine and isoniazid (3HP) vs periodic 3HP vs 6H for preventing TB among HIV-positive individuals

VINCI

Optimizing provider-initiated HIV testing, linkage, and retention in care in the district of Manhiça, Mozambique

INTE-AFRICA

Integrating and decentralizing diabetes and hypertension services in Africa

AVATAR

Searching the hidden: evaluating dengue, chikungunya and Zika autochthonous transmission in the city of Barcelona.

COVID-PREG

Eficacia de hidroxicloroquina en la prevención de la infección por SARS-CoV-2 y de la gravedad de la enfermedad de COVID-19 durante el embarazo